<DOC>
	<DOCNO>NCT00001337</DOCNO>
	<brief_summary>5-Drug Combination Chemotherapy Hematologic Toxicity Attenuation . EPOCH : Etoposide , VP-16 , NSC-141540 ; Prednisone , PRED , NSC-10023 ; Vincristine , VCR , NSC-67574 ; Cyclophosphamide , CTX , NSC-26271 ; Doxorubicin , DOX , NSC-123127 ; Granulocyte Colony-Stimulating Factor ( Amgen ) , G-CSF , NSC-614629 .</brief_summary>
	<brief_title>Dose-Adjusted EPOCH Chemotherapy Rituximab ( CD20+ ) Previously Untreated Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Background : The treatment intermediate aggressive non-Hodgkin 's lymphoma adult child commonly induce complete response sizable fraction treat population , 2/3 complete responder appear prolong disease-free survival . The present study assess activity tolerability previously untreated patient regimen EPOCH infusional chemotherapy give intensively G-CSF support . Objectives : Primary : Assess complete response ( CR ) progression-free survival ( PFS ) dose-adjusted EPOCH-Rituximab ( DA-EPOCH-R ) G-CSF agressive B-cell lymphoma . Eligibility : Non-Hodgkin 's lymphoma follow category : mediastinal gray zone lymphoma ( MGZL ) primary mediastinal B cell lymphoma ( PMBL ) . Patients great equal 12 year old . Any Stage PMBL MGZL . No prior systemic chemotherapy . HIV negative . Design : This study estimate complete response rate group previously untreated patient extent EPOCH infusional drug delivery accompany hematopoietic growth factor increase dose intensity treatment . Patients receive prednisone orally 5 day , 96 hour infusion vincristine , doxorubicin , etoposide , bolus cyclophosphamide day 5 . Cycles repeat every 21 day total 6-8 cycle . Patients CD20 express tumor ( i.e . mature B-cell lymphoma ) also receive rituximab , humanize monoclonal antibody CD20 receptor day 1 cycle . A total 348 patient enrol protocol .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>INCLUSION CRITERIA : NonHodgkin 's lymphoma follow category : mediastinal gray zone lymphoma primary mediastinal B cell lymphoma . Diagnosis confirm staff Hematopathology Section , Laboratory Pathology , NCI . Tissue block patient treated extramural site must forward NCI analysis bcl2 IHC marker within 1 month study entry . Patients great equal 12 year old . Stage Prognosis Patients : Any stage MGZL PMBL . No prior systemic chemotherapy . Patients may enter prior limitedfield radiotherapy , short course glucocorticoid and/or cyclophosphamide urgent problem diagnosis ( e.g . epidural cord compression , superior vena cava syndrome ) . HIV negative . Not pregnant nursing . Adequate major organ function [ adult : serum creatinine less equal 1.5 mg/dl creatinine clearance great 60 ml/min ; child serum CR less equal ageadjusted normal ( age 12 15 maximum serum creatinine 1.2 mg/dl age great 15 maximum serum creatinine 1.5 mg/dl ) ; bilirubin less 1.5 mg/dl ; ANC great 1,000 platelet great 100,000 ) unless impairment due organ involvement lymphoma immunemediated mechanism cause lymphoma . No active symptomatic ischemic heart disease , myocardial infarction congestive heart failure within past year . If MUGA obtain , LVEF exceed 40 % . No serious concomitant medical illness uncontrolled active infection would jeopardize patient 's ability receive regimen reasonable safety . No history unrelated ( nonlymphomatous ) neoplasm within past 5 year nonmelanoma skin cancer insitu cancer . Ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 15, 2017</verification_date>
	<keyword>Primary Mediastinal B-Cell Lymphoma</keyword>
	<keyword>CD20 +</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Anaplastic Large Cell Lymphoma</keyword>
	<keyword>De Novo</keyword>
</DOC>